US 9,808,420 B2
Drug delivery devices for delivery of ocular therapeutic agents
Casey Kopczynski, Chapel Hill, NC (US); Cheng-Wen Lin, Durham, NC (US); and Chris Sutay, Raleigh, NC (US)
Assigned to Novaer Holdings, INC., Bedminster, NJ (US)
Filed by Novaer Holdings, Inc., Bedminster, NJ (US)
Filed on Dec. 22, 2015, as Appl. No. 14/978,879.
Application 14/978,879 is a division of application No. 13/642,042, abandoned, previously published as PCT/US2011/036806, filed on May 17, 2011.
Prior Publication US 2016/0106667 A1, Apr. 21, 2016
Int. Cl. A61K 9/51 (2006.01); A61K 9/00 (2006.01); A61K 31/00 (2006.01); A61K 47/32 (2006.01); A61K 47/36 (2006.01); A61F 9/00 (2006.01); A61K 31/215 (2006.01)
CPC A61K 9/0051 (2013.01) [A61F 9/0017 (2013.01); A61K 31/00 (2013.01); A61K 31/215 (2013.01); A61K 47/32 (2013.01); A61K 47/36 (2013.01)] 8 Claims
OG exemplary drawing
 
1. A device, comprising:
a composition in the form of a matrix of an active agent and a non-water soluble polymer, wherein the active agent comprises a latanoprost free acid salt, and wherein the non-water soluble polymer comprises ethylene vinyl acetate,
a first polymer portion;
a second polymer portion fused to the first polymer portion, the second polymer portion including a recess configured to support the composition; and
a third polymer portion fused to the second polymer portion;
wherein the total diameter of the device ranges from 3-5 mm, and
wherein the device is configured to:
(a) conform to a curvature of the eye,
(b) yield an elution rate of 0.00025-0.0075 micrograms/hr of the active agent, and
(c) release 70% to 90% of the active agent over a period of at least 30 days.